event,time
31 years old ,0
female ,0
non-smoking ,0
Caucasian ,0
admitted to the hospital ,0
sudden-onset severe headache ,-840
left arm numbness ,-840
cranial computed tomography (CT) scan ,-840
grade 2 SAH ,-840
ruptured right middle cerebral artery aneurysm ,-840
percutaneous endovascular coil embolization ,-840
fever ,-672
chills ,-672
constant abdominal pain ,-672
purulent uterine discharge ,-672
sepsis ,-672
septic shock ,-672
transferred to the intensive care unit ,-672
body temperature 38.3 °C ,-672
invasive blood pressure 90/65 mmHg ,-672
heart rate 135/min ,-672
arterial oxygen saturation 82 % ,-672
mild disorientation ,-672
slower capillary refill ,-672
coarse rales ,-672
sequential organ failure assessment (SOFA) score 4 ,-672
hemoglobin 6.8 g/dL ,-672
d-dimers 4.58 μg/mL ,-672
C-reactive protein 322 mg/L ,-672
fibrinogen concentration 6.4 mL ,-672
blood culture showed E. coli ,-672
piperacillin/tazobactam ,-672
vancomycin ,-672
azithromycin ,-672
chest radiography ,-672
pulmonary nodules ,-672
transvaginal ultrasound ,-672
enlarged uterus ,-672
complete loss of zonal anatomy ,-672
abdominal magnetic resonance imaging (MRI) ,-672
splenic metastatic lesion ,-672
"serum β-human chorionic gonadotrophin (β-hCG) 232,085 mUI/mL ",-672
suction evacuation and curettage ,-672
pathology report confirmed choriocarcinoma ,-672
International Federation of Gynecology and Obstetrics (FIGO) modified WHO prognostic scoring system ,-672
total score of 12 ,-672
high risk of developing resistance to single-drug chemotherapy ,-672
multiagent chemotherapy regimen ,-24
low-dose etoposide ,-24
cisplatin ,-24
EMA/CO regimen ,0
etoposide ,0
methotrexate ,0
actinomycin D ,0
cyclophosphamide ,0
vincristine ,0
grade 3 neutropenia ,168
granulocyte colony stimulating factor (G-SCF) ,168
dose reduction of both etoposide and actinomycin D ,168
grade 2 alopecia ,168
grade 2 nausea ,168
dexamethasone ,168
ondansetron ,168
EP/EMA regimen ,336
grade 2 fatigue ,504
male condoms ,504
follow-up ,504
β-hCG levels plateaued ,504
restaging with MRI of the brain ,504
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT scan ,504
decreased pulmonary nodules ,504
decreased uterine mass ,504
low standardized uptake value (SUV) ,504
revised FIGO score 7 ,504
therapeutic regimen changed ,504
normalization of β-hCG ,720
completion of three cycles ,720
disease-free for almost two years ,1008
